Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2026)

Vanda Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $3.3 million in Q1 2026.

• Quarterly Operating Leases fell 25.84% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 25.84% YoY) and the FY2025 annual result came in at $3.0 million, down 39.5% from the prior year.
• Operating Leases improved to $3.3 million in Q1 2026 per VNDA's latest filing, from $3.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $9.7 million in Q1 2022 and troughed at $3.0 million in Q4 2025.
• A 5-year average of $6.5 million and a median of $6.5 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases gained 6.71% in 2023, then plunged 47.43% in 2024.
• Over 5 years, Operating Leases stood at $8.8 million in 2022, then grew by 6.71% to $9.4 million in 2023, then sank by 47.43% to $4.9 million in 2024, then sank by 39.5% to $3.0 million in 2025, then gained by 9.19% to $3.3 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $3.3 million, $3.0 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.